HIV-1 defence circumvented {#cesec10}
==========================

The humanised monoclonal antibody ibalizumab, which binds to human CD4, blocks HIV-1 infection and reduces viral loads in patients. However, HIV-1 strains with reduced susceptibility to ibalizumab that have lost an N-linked glycan from the viral envelope glycoprotein have emerged during clinical trials. Reasoning that this change loosens the interaction between HIV-1 and ibalizumab, researchers have engineered an N-linked glycan into ibalizumab near its interaction site with HIV-1. The carbohydrate-tagged antibody neutralised all 118 HIV-1 strains against which it was tested, including ten strains that were resistant to untagged ibalizumab.

MERS-CoV infection model in macaques {#cesec20}
====================================

The development of a rhesus macaque model of Middle East respiratory syndrome coronavirus (MERS-CoV) infection provides new information about the pathogenesis of this emerging virus. Six rhesus macaques developed a transient multifocal interstitial pneumonia after a combination of intratracheal, ocular, oral, and intranasal inoculation with HCoV-EMC/2012, the first isolate of MERS-CoV. Viral replication, which peaked early in infection, occurred mainly in alveolar pneumocytes, a tropism that might explain the severity of disease noted in people and the relatively limited human-to-human transmission of the virus.
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Inflammation in sepsis {#cesec30}
======================

Sepsis is associated with systemic inflammation, which can be triggered by exogenous pathogen-associated molecular pattern molecules or by endogenous damage-associated molecular pattern molecules. A study identifies cold-inducible RNA-binding protein (CIRP) as a damage-associated molecular pattern molecule that promotes inflammatory responses in sepsis. CIRP was upregulated in the heart and liver and released into the circulation in a rat model of sepsis. Treatment of septic animals with antisera to CIRP increased their survival rate. Thus, therapies that target CIRP might help to reduce the morbidity and mortality associated with sepsis.

Beefed up tuberculosis vaccine {#cesec40}
==============================

Although the BCG vaccine protects against disseminated childhood tuberculosis, it does not control pulmonary tuberculosis effectively. AdHu5Ag85A, a recombinant human type 5 adenovirus-based vaccine that expresses the *Mycobacterium tuberculosis* antigen Ag85A, provides protection against tuberculosis in several animal species. Now, a phase 1 study indicates that AdHu5Ag85A is well tolerated in people, that it is immunogenic (particularly in individuals who have previously been immunised with BCG) and that pre-existing anti-AdHu5 immunity has little effect on its potency.

Enteric pathogen evolution {#cesec50}
==========================

*Shigella sonnei* accounts for about a sixth of the global dysentery burden. It first emerged in Europe about 500 years ago, and a multidrug-resistant clade of *S sonnei* known as Global III is now the dominant cause of dysentery in many endemic regions. An analysis of the genomic sequence of 263 *S sonnei* isolates obtained in Vietnam, where *S sonnei* recently replaced *Shigella flexneri* as the major cause of dysentery, indicates that *S sonnei* arrived in Vietnam in the early 1980s and that it has undergone localised clonal expansion, during which several pathogenesis-boosting mutations have been fixed in the bacterial population.

*C difficile* infection sources {#cesec60}
===============================

It is widely believed that *Clostridium difficile* infection is transmitted mainly within health-care settings. Consequently, control guidelines focus on prevention of transmission from patients with symptoms. However, whole-genome sequencing of *C difficile* isolates obtained from patients with symptoms of *C difficile* infection in Oxfordshire, UK, over a 3·6 year period indicates that only 35% of cases were genetically related to at least one previous case. Of these cases, only 38% had close hospital contact with another patient. Notably, 45% of cases were genetically unrelated to any previous case. Thus, many *C difficile* infections may arise from genetically diverse sources rather than from patients with symptoms.

Antimalarial development {#cesec70}
========================

High throughput screening of compound libraries has identified thousands of candidates for antimalarial drugs. But which leads should be selected for further development? An in-vitro system in which *Plasmodium falciparum* is exposed to dynamic fluctuations in drug concentrations that mimic the fluctuations seen in vivo might simplify and speed up the development of new antimalarial drugs. In a validation of the system, in which *P falciparum* is grown in hollow-fibre reactors, researchers show that chloroquine works best when given as an infusion whereas artemisinin works best when given in short-lived spurts.
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